APOE: Should I get tested?

What APOE is

The APOE gene provides instructions for apolipoprotein E, a protein involved in transporting cholesterol and other fats. It also participates in several processes relevant to the brain.

The three common forms are called e2, e3, and e4. Each person inherits one APOE copy from each biological parent, producing combinations such as e3/e3, e3/e4, or e4/e4.

APOE e4 is associated with a higher probability of Alzheimer's disease. Two copies generally confer more risk than one. APOE e2 is associated with lower risk in many studies. None of these combinations guarantees or excludes the disease.

The size of the association varies with age, ancestry, sex, study design, and the outcome being measured. A result should not be presented as one universal lifetime percentage that applies equally to everyone.

If you do not have cognitive symptoms

For a person without symptoms, APOE testing is usually a risk estimate rather than a medical diagnosis. It cannot say whether Alzheimer's disease will occur, when it might begin, or how it would progress.

Before testing out of curiosity or because of a family history, ask what decision the result would change. Would either answer alter medical care, research participation, family planning, financial planning, or emotional well-being? Would you want to know a higher-risk result if no disease were currently detectable?

A family history can still be discussed with a clinician without first obtaining APOE testing. Healthy brain-aging recommendations do not depend on carrying APOE e4, and a lower-risk genotype is not a reason to ignore new symptoms or general health.

If you are worried about current symptoms

APOE is not a stand-alone diagnostic test. People with Alzheimer's can lack APOE e4, and people with APOE e4 can remain free of dementia.

If symptoms are present, the evaluation begins with the history, daily function, neurologic examination, cognitive assessment, and appropriate imaging or biomarkers. Tests that assess Alzheimer's-related amyloid or tau biology answer a different and more direct question than APOE does.

An APOE result may add context, but it should not be used to explain symptoms by itself.

If you are considering amyloid-lowering treatment

This is the setting in which APOE now has a clear treatment-related role. Lecanemab and donanemab can cause amyloid-related imaging abnormalities, called ARIA, which may involve brain swelling or bleeding. People with two APOE e4 copies have a higher incidence of ARIA than people with one or no e4 copies.

Current FDA prescribing information states that APOE e4 status should be tested before treatment to inform the ARIA risk discussion. The genotype is one part of that decision. MRI findings, medications such as anticoagulants, other medical risks, expected benefit, and the patient's preferences also matter.

APOE does not establish eligibility for treatment. The clinical stage and evidence of amyloid pathology must be assessed separately.

If you already have a consumer result

A direct-to-consumer result should be interpreted in the context of the method used and the question you are trying to answer. Some services test only selected variants. Downloaded raw data interpreted by a third party may be especially prone to error or overstatement.

Do not make a major medical decision from a consumer report alone. If the result could affect treatment or another clinical decision, ask whether confirmation in a clinical laboratory is needed.

Also review how the company stores, shares, or uses genetic information. Once raw genetic data are moved to another service, the original privacy protections may no longer apply.

What the result may mean for relatives

Because APOE is inherited, learning your genotype also provides partial information about biological relatives. They may have different preferences about knowing that information.

APOE is not the same as a confirmed pathogenic variant in APP, PSEN1, or PSEN2. A relative's APOE result cannot identify an autosomal dominant Alzheimer's family, and it should not be used to predict which family member will become ill.

Consider the implications before testing

Genetic information can affect anxiety, family relationships, and planning. In the United States, GINA protects against many uses of genetic information in health insurance and employment, but it does not provide the same federal protection for life, disability, or long-term care insurance. State laws vary.

A genetic counselor or clinician familiar with Alzheimer's genetics can help separate four different reasons for testing: future risk, current diagnosis, research participation, and treatment safety.

A short decision guide

Testing may be clinically useful now if you are being evaluated for an amyloid-lowering treatment and the result will inform a discussion of ARIA risk.

Testing may require a broader genetics evaluation if your family has several people with unusually early symptoms or a known pathogenic variant. APOE alone does not answer that question.

Testing may provide limited actionable information if you have no symptoms and are seeking a precise forecast of future Alzheimer's disease. APOE cannot provide that forecast.

The best first question is not, "Can I learn my APOE type?" It is, "What decision would the answer change?"